AMVUTTRA® (vutrisiran) - RNAi Therapy

This interactive PDF provides an overview of ATTR-CM and RNAi therapeutics, and offers a deep dive into the vutrisiran data in ATTR-CM from the HELIOS-B trial, including the primary and additional analyses. Alnylam's ongoing commitment to ATTR amyloidosis is reflected in a summary of the current pipeline and TRITON-CM study design.

ATTR-CM HELIOS-B Data Summary deck provides a comprehensive overview of the HELIOS-B results. Also includes information on ATTR-CM and the MOA of RNAi therapeutics.

This material is a short summary of HELIOS-B primary medical and scientific publications (including peer-reviewed medical journal articles and scientific conference presentations)

This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.